董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Ann Merrifield | 女 | Director | 66 | 8.98万美元 | 未持股 | 2017-05-11 |
| Cristina Csimma | 女 | Director | 58 | 8.77万美元 | 未持股 | 2017-05-11 |
| Mary Ann Gray | 女 | Director | 64 | 8.84万美元 | 未持股 | 2017-05-11 |
| James Arthur Geraghty | 男 | Chairman of the Board | 62 | 15.30万美元 | 未持股 | 2017-05-11 |
| Alicia Secor | 女 | Director, President and Chief Executive Officer | 54 | 134.43万美元 | 未持股 | 2017-05-11 |
| Frank M. Armstrong | 男 | Director | 60 | 10.64万美元 | 未持股 | 2017-05-11 |
| Nikin Patel | 男 | Director and Chief Operating Officer | 44 | 59.97万美元 | 未持股 | 2017-05-11 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Bridget Martell | 女 | Chief Medical Officer | 51 | 66.38万美元 | 未持股 | 2017-05-11 |
| Jeffrey Young | 男 | Chief Financial Officer | 44 | 未披露 | 未持股 | 2017-05-11 |
| Alicia Secor | 女 | Director, President and Chief Executive Officer | 54 | 134.43万美元 | 未持股 | 2017-05-11 |
| Nikin Patel | 男 | Director and Chief Operating Officer | 44 | 59.97万美元 | 未持股 | 2017-05-11 |
董事简历
中英对照 | 中文 | 英文- Ann Merrifield
-
Ann Merrifield，自2015年7月起担任公司董事；2012年12月至2014年7月间担任PathoGenetix, Inc.（基因组学技术）的总裁兼首席执行官。在加入PathoGenetix, Inc.之前，她在， Ms. Merrifield served an 18-year tenure at Genzyme （现为Sanofi S.A.所有，多元化全球生物技术公司）任职18年，其间，她担任了业务能力高级副总裁、Genzyme Biosurgery的总裁、Genzyme Genetics的总裁等职位。在加入Genzyme之前，她是Bain and Company （全球战略咨询）的合伙人，也是Aetna Life & Casualty的投资官。她是Flexion Therapeutics （非阿片嘞镇痛疗法）和InVivo Therapeutics （脊髓损伤）的董事，也是两家大众共同投资基金的理事。她获得了the University of Maine的动物学学士学位、教育学硕士学位，以及the Amos Tuck School of Business at Dartmouth College的工商管理硕士学位。
Ann Merrifieldhas been a director of the Company since July 2015. She was the President and Chief Executive Officer of PathoGenetix, Inc. genomics technology, from December 2012 to July 2014. PathoGenetix, Inc. filed for Chapter 7 bankruptcy in July 2014. Prior to joining PathoGenetix, Inc., Ms. Merrifield served an 18-year tenure at Genzyme (now owned by Sanofi S.A.), a diversified, global biotechnology company. During her time at Genzyme, Ms. Merrifield served, among other roles, as Senior Vice President, Business Excellence, President of Genzyme Biosurgery, and President of Genzyme Genetics. Prior to joining Genzyme, Ms. Merrifield was a Partner at Bain and Company (global strategy consulting) and an Investment Officer at Aetna Life & Casualty. She is also a director of Flexion Therapeutics (non-opioid pain therapies) and InVivo Therapeutics (spinal cord injury), and is a trustee of two MassMutual investment funds. Ms. Merrifield earned a B.A. in Zoology and a Master of Education from the University of Maine, and an M.B.A from the Amos Tuck School of Business at Dartmouth College. - Ann Merrifield，自2015年7月起担任公司董事；2012年12月至2014年7月间担任PathoGenetix, Inc.（基因组学技术）的总裁兼首席执行官。在加入PathoGenetix, Inc.之前，她在， Ms. Merrifield served an 18-year tenure at Genzyme （现为Sanofi S.A.所有，多元化全球生物技术公司）任职18年，其间，她担任了业务能力高级副总裁、Genzyme Biosurgery的总裁、Genzyme Genetics的总裁等职位。在加入Genzyme之前，她是Bain and Company （全球战略咨询）的合伙人，也是Aetna Life & Casualty的投资官。她是Flexion Therapeutics （非阿片嘞镇痛疗法）和InVivo Therapeutics （脊髓损伤）的董事，也是两家大众共同投资基金的理事。她获得了the University of Maine的动物学学士学位、教育学硕士学位，以及the Amos Tuck School of Business at Dartmouth College的工商管理硕士学位。
- Ann Merrifieldhas been a director of the Company since July 2015. She was the President and Chief Executive Officer of PathoGenetix, Inc. genomics technology, from December 2012 to July 2014. PathoGenetix, Inc. filed for Chapter 7 bankruptcy in July 2014. Prior to joining PathoGenetix, Inc., Ms. Merrifield served an 18-year tenure at Genzyme (now owned by Sanofi S.A.), a diversified, global biotechnology company. During her time at Genzyme, Ms. Merrifield served, among other roles, as Senior Vice President, Business Excellence, President of Genzyme Biosurgery, and President of Genzyme Genetics. Prior to joining Genzyme, Ms. Merrifield was a Partner at Bain and Company (global strategy consulting) and an Investment Officer at Aetna Life & Casualty. She is also a director of Flexion Therapeutics (non-opioid pain therapies) and InVivo Therapeutics (spinal cord injury), and is a trustee of two MassMutual investment funds. Ms. Merrifield earned a B.A. in Zoology and a Master of Education from the University of Maine, and an M.B.A from the Amos Tuck School of Business at Dartmouth College.
- Cristina Csimma
-
Cristina Csimma，女，药学博士，自2010年9月起担任本公司董事。自2012年11月起，担任Cydan, Inc.负责罕见疾病治疗的首席执行官。之前在生物制药和投资行业以及政府和患者组织担任战略咨询的角色。2009年1月至2011年5月担任Virdante制药公司负责药物开发的副总裁。从2006年到2008年担任Clarus Ventures有限责任公司（生命科学风险投资）的主管。2001至2006年担任惠氏研究（制药）的 资深总监/董事，负责实验医学和转化研究。2000至2001年担任惠氏研究（制药）负责临床研究和开发的主任。此前担任多个职位，包括1988年至2000年担任遗传学研究所临床研究的副主任，自1983年至1988年于Dana-Farber癌症研究所担任临床药师。持有美国马萨诸塞药学院及联合健康科学学院的药学学士学位和博士学位，并从东北大学获得卫生专业硕士学位。
Cristina Csimma is a biopharmaceutical leader and strategic advisor with decades of experience in biotechnology, large pharma, and venture capital. Dr. Csimma currently serves on the board of directors of Syncona Partners, LLP (LON: SYNC), having been elected to its board of directors in February 2022. She also serves as a board director and a member of the compensation committee of Palisade Bio, Inc. (Nasdaq: PALI), having been elected to its board of directors in 2017. She also serves as the chair of the board of directors of Caraway Therapeutics, Inc. since 2019 (executive chair in 2019). Dr. Csimma also serves on advisory boards, including the Muscular Dystrophy Association Venture Philanthropy Scientific Advisory Committee since 2006; the Harvard and Brigham and Women's Hospital MRCT Center External Advisory Board since 2015; the TREAT-NMD Advisory Committee for Therapeutics (TACT) since 2009; and the Executive Oversight Board to the National Institutes of Health (NIH) NeuroNext Network since 2013.Dr. Csimma previously served as chair of the board of directors of Forendo Pharma between 2020 and 2021 (executive chair in 2021) when it was acquired by Organon & Co. Dr. Csimma also previously served as a director on the boards of Seneca Biopharma, Inc. (Nasdaq: SNCA; formerly Neuralstem Inc., from 2017 until 2021 when it merged with Leading BioSciences Inc. to form Palisade Bio), Juniper Pharmaceuticals, Inc. (from 2010 until its acquisition by Catalent, Inc. in 2018), and Vtesse Inc. (from 2014 until its acquisition by Sucampo Pharmaceuticals, Inc. in 2017). Dr. Csimma was the executive chair and a senior advisor of Exonics Therapeutics, Inc. (from 2016 to 2017), and was President, founding CEO, and board director of Cydan Inc. from 2012 to 2014. She also served on the board of directors of T1D Exchange (non-profit Type 1 Diabetes) from 2018 to 2020 and the NIH Blueprint Neurotherapeutics Network External Oversight Committee from 2014 to 2018, was Vice President of Drug Development at Virdante Pharmaceuticals Inc. from 2009 to 2011, Principal at Clarus Ventures LLC (now Blackstone Life Science), and held roles of increasing responsibility in Clinical Development and Translational Research at Wyeth (now Pfizer Inc.), Genetics Institute, and Dana Farber Cancer Institute. Dr. Csimma holds both a Doctor of Pharmacy and a Bachelor of Science in Pharmacy from the Massachusetts College of Pharmacy and Allied Health Sciences, as well as a Master of Health Professions from Northeastern University. - Cristina Csimma，女，药学博士，自2010年9月起担任本公司董事。自2012年11月起，担任Cydan, Inc.负责罕见疾病治疗的首席执行官。之前在生物制药和投资行业以及政府和患者组织担任战略咨询的角色。2009年1月至2011年5月担任Virdante制药公司负责药物开发的副总裁。从2006年到2008年担任Clarus Ventures有限责任公司（生命科学风险投资）的主管。2001至2006年担任惠氏研究（制药）的 资深总监/董事，负责实验医学和转化研究。2000至2001年担任惠氏研究（制药）负责临床研究和开发的主任。此前担任多个职位，包括1988年至2000年担任遗传学研究所临床研究的副主任，自1983年至1988年于Dana-Farber癌症研究所担任临床药师。持有美国马萨诸塞药学院及联合健康科学学院的药学学士学位和博士学位，并从东北大学获得卫生专业硕士学位。
- Cristina Csimma is a biopharmaceutical leader and strategic advisor with decades of experience in biotechnology, large pharma, and venture capital. Dr. Csimma currently serves on the board of directors of Syncona Partners, LLP (LON: SYNC), having been elected to its board of directors in February 2022. She also serves as a board director and a member of the compensation committee of Palisade Bio, Inc. (Nasdaq: PALI), having been elected to its board of directors in 2017. She also serves as the chair of the board of directors of Caraway Therapeutics, Inc. since 2019 (executive chair in 2019). Dr. Csimma also serves on advisory boards, including the Muscular Dystrophy Association Venture Philanthropy Scientific Advisory Committee since 2006; the Harvard and Brigham and Women's Hospital MRCT Center External Advisory Board since 2015; the TREAT-NMD Advisory Committee for Therapeutics (TACT) since 2009; and the Executive Oversight Board to the National Institutes of Health (NIH) NeuroNext Network since 2013.Dr. Csimma previously served as chair of the board of directors of Forendo Pharma between 2020 and 2021 (executive chair in 2021) when it was acquired by Organon & Co. Dr. Csimma also previously served as a director on the boards of Seneca Biopharma, Inc. (Nasdaq: SNCA; formerly Neuralstem Inc., from 2017 until 2021 when it merged with Leading BioSciences Inc. to form Palisade Bio), Juniper Pharmaceuticals, Inc. (from 2010 until its acquisition by Catalent, Inc. in 2018), and Vtesse Inc. (from 2014 until its acquisition by Sucampo Pharmaceuticals, Inc. in 2017). Dr. Csimma was the executive chair and a senior advisor of Exonics Therapeutics, Inc. (from 2016 to 2017), and was President, founding CEO, and board director of Cydan Inc. from 2012 to 2014. She also served on the board of directors of T1D Exchange (non-profit Type 1 Diabetes) from 2018 to 2020 and the NIH Blueprint Neurotherapeutics Network External Oversight Committee from 2014 to 2018, was Vice President of Drug Development at Virdante Pharmaceuticals Inc. from 2009 to 2011, Principal at Clarus Ventures LLC (now Blackstone Life Science), and held roles of increasing responsibility in Clinical Development and Translational Research at Wyeth (now Pfizer Inc.), Genetics Institute, and Dana Farber Cancer Institute. Dr. Csimma holds both a Doctor of Pharmacy and a Bachelor of Science in Pharmacy from the Massachusetts College of Pharmacy and Allied Health Sciences, as well as a Master of Health Professions from Northeastern University.
- Mary Ann Gray
-
Mary Ann Gray自2019年7月起担任董事会成员。自2018年以来，她还担任Sarepta Therapeutics, Inc.的董事会成员。从2010年到2018年，Gray博士担任Senomyx Inc.(一家致力于开发添加剂以放大食品中的某些味道和气味的生物技术公司)的董事会成员。2016年4月至2018年8月，她还担任女性健康公司Juniper Pharmaceuticals的董事会成员和审计委员会主席。2014年11月至2016年12月，她担任TetraLogic(一家上市的临床阶段生物制药公司，专注于肿瘤学和传染病)的董事会成员。从2005年到2016年，她还担任Acadia Pharmaceuticals的董事会成员，专注于CNS疗法的商业化。2001年至2016年，她担任罕见病公司Dyax Corp.的董事会成员，该公司于2016年被Shire收购。她是Gray Strategic Advisors, LLC(生物技术战略规划和咨询公司)的总裁。她拥有杰出的科学背景，完成了肿瘤生物学的药理学研究，包括治疗对心膜的影响，并开始了她在生物技术领域的职业生涯，作为一名专注于新药开发的科学家。在成为高级分析师和投资组合经理之前，她曾从事股票研究。她持有University of South Carolina的理学士学位和University of Vermont的药理学博士学位，并在Northwestern University Medical School和Yale University School of Medicine完成了博士后工作。
Mary Ann Gray has served as a member of the Board since July 2019. Since 2018 Dr. Gray has also served on the board of directors of Sarepta Therapeutics, Inc. From 2010 to 2018 Dr. Gray served as a member of the board of Senomyx Inc., a biotechnology company working toward developing additives to amplify certain flavors and smells in foods. Dr. Gray also served as a member of the board and audit committee chair of Juniper Pharmaceuticals, a women's health company, from April 2016 to August 2018. From November 2014 to December 2016 Dr. Gray served as a member of the board of TetraLogic, a publicly-held clinical-stage biopharmaceutical company focused on oncology and infectious diseases. Dr. Gray also served as a Board member of Acadia Pharmaceuticals, focused on commercialization of CNS therapies, from 2005 to 2016. Dr. Gray served as a Board member of Dyax Corp., a rare disease company acquired by Shire in 2016 from 2001 to 2016. Dr. Gray is the President of Gray Strategic Advisors, LLC, a biotechnology strategic planning and advisory firm. Dr. Gray has a distinguished scientific background, completing pharmacology research in tumor biology, including the impact of therapeutics on cardiac membranes and beginning her career in biotechnology as a scientist focused on new drug development. She subsequently worked in equities research before becoming a senior analyst and portfolio manager. Dr. Gray received a B.S. from University of South Carolina, a Ph.D. in pharmacology from the University of Vermont, and completed her post-doctoral work at Northwestern University Medical School and at the Yale University School of Medicine. - Mary Ann Gray自2019年7月起担任董事会成员。自2018年以来，她还担任Sarepta Therapeutics, Inc.的董事会成员。从2010年到2018年，Gray博士担任Senomyx Inc.(一家致力于开发添加剂以放大食品中的某些味道和气味的生物技术公司)的董事会成员。2016年4月至2018年8月，她还担任女性健康公司Juniper Pharmaceuticals的董事会成员和审计委员会主席。2014年11月至2016年12月，她担任TetraLogic(一家上市的临床阶段生物制药公司，专注于肿瘤学和传染病)的董事会成员。从2005年到2016年，她还担任Acadia Pharmaceuticals的董事会成员，专注于CNS疗法的商业化。2001年至2016年，她担任罕见病公司Dyax Corp.的董事会成员，该公司于2016年被Shire收购。她是Gray Strategic Advisors, LLC(生物技术战略规划和咨询公司)的总裁。她拥有杰出的科学背景，完成了肿瘤生物学的药理学研究，包括治疗对心膜的影响，并开始了她在生物技术领域的职业生涯，作为一名专注于新药开发的科学家。在成为高级分析师和投资组合经理之前，她曾从事股票研究。她持有University of South Carolina的理学士学位和University of Vermont的药理学博士学位，并在Northwestern University Medical School和Yale University School of Medicine完成了博士后工作。
- Mary Ann Gray has served as a member of the Board since July 2019. Since 2018 Dr. Gray has also served on the board of directors of Sarepta Therapeutics, Inc. From 2010 to 2018 Dr. Gray served as a member of the board of Senomyx Inc., a biotechnology company working toward developing additives to amplify certain flavors and smells in foods. Dr. Gray also served as a member of the board and audit committee chair of Juniper Pharmaceuticals, a women's health company, from April 2016 to August 2018. From November 2014 to December 2016 Dr. Gray served as a member of the board of TetraLogic, a publicly-held clinical-stage biopharmaceutical company focused on oncology and infectious diseases. Dr. Gray also served as a Board member of Acadia Pharmaceuticals, focused on commercialization of CNS therapies, from 2005 to 2016. Dr. Gray served as a Board member of Dyax Corp., a rare disease company acquired by Shire in 2016 from 2001 to 2016. Dr. Gray is the President of Gray Strategic Advisors, LLC, a biotechnology strategic planning and advisory firm. Dr. Gray has a distinguished scientific background, completing pharmacology research in tumor biology, including the impact of therapeutics on cardiac membranes and beginning her career in biotechnology as a scientist focused on new drug development. She subsequently worked in equities research before becoming a senior analyst and portfolio manager. Dr. Gray received a B.S. from University of South Carolina, a Ph.D. in pharmacology from the University of Vermont, and completed her post-doctoral work at Northwestern University Medical School and at the Yale University School of Medicine.
- James Arthur Geraghty
-
James Arthur Geraghty先生，于2018年7月18日获委任为北海康成制药有限公司独立非执行董事。Geraghty先生自2017年5月起担任公司的全资附属公司北海康成医药科技的独立非执行董事。Geraghty先生负责监督董事会并为董事会提供独立判断。Geraghty先生在业务发展、战略及营运方面拥有约30年管理经验。于2013年5月至2016年12月，Geraghty先生为Third Rock Ventures的驻场企业家，负责公司组建及治理。在此之前，Geraghty先生于2011年4月至2012年12月期间担任Sanofi S.A.的高级副总裁，负责战略及业务发展。Geraghty先生于1992年至2011年任职于美国健赞公司，其在此担任的最后职位是负责国际开发的高级副总裁。于1993年至2007年，Geraghty先生担任Genzyme Transgenics Corporation的董事会主席及首席执行官。此前，Geraghty先生在贝恩资本开启职业生涯，负责医疗健康策略咨询。Geraghty先生自2018年5月及2017年11月起分别担任Orchard Therapeutics（纳斯达克：ORTX）及Pieris Pharmaceuticals（纳斯达克：PIRS）的董事会主席。Geraghty先生亦自2016年10月、2014年1月及2013年7月起分别担任Fulcrum Therapeutics（纳斯达克：PIRS）、Voyager Therapeutics（纳斯达克：VYGR）及Idera Pharmaceuticals（纳斯达克：IDRA）的独立非雇员董事。Geraghty先生于1980年5月在乔治敦大学获得心理学学士学位及在耶鲁大学法学院获得法学博士学位。
James Arthur Geraghty has served on Idera Pharmaceuticals, Inc. Board of Directors since 2013 and as chair of Idera Pharmaceuticals, Inc. Board of Directors from that time until 2021. Mr. Geraghty is an industry leader with over 35 years of strategic and leadership experience, including more than 25 years as a senior member of executive teams at biotechnology companies developing and commercializing innovative therapies. From 2013 to 2016, Mr. Geraghty was an Entrepreneur in Residence at Third Rock Ventures, a leading biotech venture fund. From 2011 to 2012, he served as a Senior Vice President of Sanofi S.A., a global healthcare company. Prior to that, he served in various senior management roles at Genzyme Corporation, or Genzyme, a biotechnology company, from 1992 to 2011, including as Senior Vice President of International Development and President of Genzyme Europe. Mr. Geraghty currently serves as chairman of the board of Orchard Therapeutics plc and Pieris Pharmaceuticals, Inc. and as a member of the board of Voyager Therapeutics, Inc., and Fulcrum Therapeutics, Inc. He also previously served as a director of bluebird bio, Inc. and GTC Biotherapeutics, Inc. - James Arthur Geraghty先生，于2018年7月18日获委任为北海康成制药有限公司独立非执行董事。Geraghty先生自2017年5月起担任公司的全资附属公司北海康成医药科技的独立非执行董事。Geraghty先生负责监督董事会并为董事会提供独立判断。Geraghty先生在业务发展、战略及营运方面拥有约30年管理经验。于2013年5月至2016年12月，Geraghty先生为Third Rock Ventures的驻场企业家，负责公司组建及治理。在此之前，Geraghty先生于2011年4月至2012年12月期间担任Sanofi S.A.的高级副总裁，负责战略及业务发展。Geraghty先生于1992年至2011年任职于美国健赞公司，其在此担任的最后职位是负责国际开发的高级副总裁。于1993年至2007年，Geraghty先生担任Genzyme Transgenics Corporation的董事会主席及首席执行官。此前，Geraghty先生在贝恩资本开启职业生涯，负责医疗健康策略咨询。Geraghty先生自2018年5月及2017年11月起分别担任Orchard Therapeutics（纳斯达克：ORTX）及Pieris Pharmaceuticals（纳斯达克：PIRS）的董事会主席。Geraghty先生亦自2016年10月、2014年1月及2013年7月起分别担任Fulcrum Therapeutics（纳斯达克：PIRS）、Voyager Therapeutics（纳斯达克：VYGR）及Idera Pharmaceuticals（纳斯达克：IDRA）的独立非雇员董事。Geraghty先生于1980年5月在乔治敦大学获得心理学学士学位及在耶鲁大学法学院获得法学博士学位。
- James Arthur Geraghty has served on Idera Pharmaceuticals, Inc. Board of Directors since 2013 and as chair of Idera Pharmaceuticals, Inc. Board of Directors from that time until 2021. Mr. Geraghty is an industry leader with over 35 years of strategic and leadership experience, including more than 25 years as a senior member of executive teams at biotechnology companies developing and commercializing innovative therapies. From 2013 to 2016, Mr. Geraghty was an Entrepreneur in Residence at Third Rock Ventures, a leading biotech venture fund. From 2011 to 2012, he served as a Senior Vice President of Sanofi S.A., a global healthcare company. Prior to that, he served in various senior management roles at Genzyme Corporation, or Genzyme, a biotechnology company, from 1992 to 2011, including as Senior Vice President of International Development and President of Genzyme Europe. Mr. Geraghty currently serves as chairman of the board of Orchard Therapeutics plc and Pieris Pharmaceuticals, Inc. and as a member of the board of Voyager Therapeutics, Inc., and Fulcrum Therapeutics, Inc. He also previously served as a director of bluebird bio, Inc. and GTC Biotherapeutics, Inc.
- Alicia Secor
-
Alicia Secor.， 自2014年1月起担任首席商务官。她在制药、生物技术和医疗设备方面有着20多年的经验。她在通过生命周期发展各个阶段引领商业发展并进行产品全球扩张领域，包括发射前和后期的商业阶段涵盖多个治疗领域，包括代谢性疾病，有着良好的记录。从2013年8月到2013年10月担任Synageva BioPharma Corp高级副总裁和首席运营官。之前从1998年11月到2013年7月，她在 Genzyme Corporation（一家Sanofi 公司）工作15年，担任多个领导职位，最近的职位是担任Metabolic Diseases（一家全球业务，包括5大产品销售，其中又包括治疗罕见疾病的两种产品）副总裁和总经理。在此之前，她还担任Biosurgical Specialties（一家手术设备业务，重点关注防粘粘和生物材料的新应用）副总裁和总经理。在Genzyme任职期间，她在通过临床开发和负责建立以及执行商业开发和推出，一般管理和全球扩张以推广产品方面发挥了很大作用。她成功地带领了多元战略业务开发拍卖会，负责全球的P&L，并建立高绩效团队，从而带来了多个业务的持续增长和盈利能力。加入 Genzyme之前，她在 Alkermes plc 的业务开发部门、Centocor, Inc.（一家Johnson & Johnson公司）的临床和商务运营部门担任多个职位；她在 Pfizer Inc.担任以医院为基础的销售代表开启自己的职业生涯。她持有东北大学（Northeastern University）工商管理硕士学位以及the University of New Hampshire医疗保健管理理学学士学位。
Alicia Secor joined our board of directors in December 2017.Ms. Secor served as President and Chief Executive Officer of Juniper Pharmaceuticals, Inc., a Nasdaq listed pharmaceutical company from August 2016 until August 2018 the date the company was acquired by Catalent, Inc. Previously, she served as the chief commercial officer of Zafgen Inc., a biopharmaceutical company, from January 2014 to July 2016. From August 2013 to October 2013 she served as senior vice president and chief operating officer of Synageva BioPharma Corp., a biotechnology company. Previously, from November 1998 to July 2013 Ms. Secor spent 15 years at Genzyme, a biotechnology company, where she held various leadership positions, most recently as vice president and general manager of Metabolic Diseases, a global business with five marketed products, including two products for orphan diseases. Prior to this role, she was vice president and general manager of Biosurgical Specialties, a surgical device business focused on adhesion prevention and other novel applications for biomaterials. Prior to Genzyme, Ms. Secor held positions at Alkermes, Inc. in business development, at Centocor, Inc. a Johnson & Johnson company in clinical and commercial operations, and began her career at Pfizer Inc. as a hospital-based sales representative. Ms. Secor also serves as a member of the board of directors for the Foundation for Prader-Willi Research. She received her M.B.A. from Northeastern University and her B.S. in Healthcare Administration from the University of New Hampshire. - Alicia Secor.， 自2014年1月起担任首席商务官。她在制药、生物技术和医疗设备方面有着20多年的经验。她在通过生命周期发展各个阶段引领商业发展并进行产品全球扩张领域，包括发射前和后期的商业阶段涵盖多个治疗领域，包括代谢性疾病，有着良好的记录。从2013年8月到2013年10月担任Synageva BioPharma Corp高级副总裁和首席运营官。之前从1998年11月到2013年7月，她在 Genzyme Corporation（一家Sanofi 公司）工作15年，担任多个领导职位，最近的职位是担任Metabolic Diseases（一家全球业务，包括5大产品销售，其中又包括治疗罕见疾病的两种产品）副总裁和总经理。在此之前，她还担任Biosurgical Specialties（一家手术设备业务，重点关注防粘粘和生物材料的新应用）副总裁和总经理。在Genzyme任职期间，她在通过临床开发和负责建立以及执行商业开发和推出，一般管理和全球扩张以推广产品方面发挥了很大作用。她成功地带领了多元战略业务开发拍卖会，负责全球的P&L，并建立高绩效团队，从而带来了多个业务的持续增长和盈利能力。加入 Genzyme之前，她在 Alkermes plc 的业务开发部门、Centocor, Inc.（一家Johnson & Johnson公司）的临床和商务运营部门担任多个职位；她在 Pfizer Inc.担任以医院为基础的销售代表开启自己的职业生涯。她持有东北大学（Northeastern University）工商管理硕士学位以及the University of New Hampshire医疗保健管理理学学士学位。
- Alicia Secor joined our board of directors in December 2017.Ms. Secor served as President and Chief Executive Officer of Juniper Pharmaceuticals, Inc., a Nasdaq listed pharmaceutical company from August 2016 until August 2018 the date the company was acquired by Catalent, Inc. Previously, she served as the chief commercial officer of Zafgen Inc., a biopharmaceutical company, from January 2014 to July 2016. From August 2013 to October 2013 she served as senior vice president and chief operating officer of Synageva BioPharma Corp., a biotechnology company. Previously, from November 1998 to July 2013 Ms. Secor spent 15 years at Genzyme, a biotechnology company, where she held various leadership positions, most recently as vice president and general manager of Metabolic Diseases, a global business with five marketed products, including two products for orphan diseases. Prior to this role, she was vice president and general manager of Biosurgical Specialties, a surgical device business focused on adhesion prevention and other novel applications for biomaterials. Prior to Genzyme, Ms. Secor held positions at Alkermes, Inc. in business development, at Centocor, Inc. a Johnson & Johnson company in clinical and commercial operations, and began her career at Pfizer Inc. as a hospital-based sales representative. Ms. Secor also serves as a member of the board of directors for the Foundation for Prader-Willi Research. She received her M.B.A. from Northeastern University and her B.S. in Healthcare Administration from the University of New Hampshire.
- Frank M. Armstrong
-
Frank M. Armstrong自2013年9月起担任本公司董事。2010年12月至2011年12月领导默克雪兰诺公司的医学科学和创新研发。1998至2001年领导拜耳公司的全球产品开发。在1996至1998年领导在捷利康的全球医疗组织。2008至2010年还担任过Fulcrum制药有限公司的专业服务/ CRO的首席执行官；自2006年至2007年担任CURAGEN公司（肿瘤治疗）的总裁及行政总裁； 2003至2004年担任Provensis制药（BTG PLC（医疗）的附属公司）的行政总裁；2002至2003年担任PHOQUS制药有限公司的行政总裁。毕业于苏格兰爱丁堡大学，获生物化学医学士荣誉学位。在1994年当选为医药医师学院院士（FFPM），于1993年当选为爱丁堡（FRCPE）皇家内科医学院院士。自2013年6月起至今担任Summit PLC（药物发现和开发）的非执行主席； 自2012年4月起担任Xceleron公司（生物分析服务）的董事长，自2009年11月担任Actino制药的非执行董事； 自2013年9月起担任Entelos公司（生物模拟）的董事长；自2013年9月起担任CardioRentis有限公司（生物制药）的董事长。自2009年以来担任医疗保健版税合作伙伴的战略顾问委员会委员，自2009年以来担任英国的“爱非洲”慈善基金的主席。
Frank M. Armstrong has been a director of the Company since September 2013. Dr. Armstrong led Medical Science and Innovation in R&D at Merck Serono from 2010 to 2011 and previously led Worldwide Product Development at Bayer AG from 1998 to 2001 and the Worldwide Medical Organization at Zeneca from 1996 to 1998. He also served as Chief Executive Officer of Fulcrum Pharma plc professional services/CRO from 2008 to 2010; President and Chief Executive Officer of CuraGen Corp. (oncology therapeutics) from 2006 to 2007; Chief Executive Officer of Bioaccelerate from 2005 to 2006; Chief Executive Officer of Provensis Pharmaceuticals, a subsidiary of BTG PLC (healthcare), from 2003 to 2004; and Chief Executive Officer of Phoqus Pharmaceuticals plc (drug delivery) from 2002 to 2003. Since 2012 Dr. Armstrong has served as a Director of Dr. Frank M Armstrong Consulting Ltd. Dr. Armstrong holds an honours degree in Biochemistry and MBChB in Medicine from the University of Edinburgh in Scotland. He was elected as a Fellow of the Faculty of Pharmaceutical Physicians (FFPM) in 1994 and Fellow of Royal College of Physicians, Edinburgh (FRCPE) in 1993. Dr. Armstrong is currently the non-executive Chairman of Summit plc (drug discovery and development), a position he has held since June 2013; the non-executive Chairman of Caldan Therapeutics (metabolic disease), a position he has held since March 2016; the non-executive Chairman of Faron Pharmaceuticals (drug discovery and development), a position he has held since September 2015; and a non-executive Director of Mereo Biopharma (drug discovery and development), a position he has held since July 2015. He served as the executive Chairman of Asceneuron SA (biotechnology) from 2012 to 2013; the non-executive Chairman of RedXPharma (drug discovery and development) from 2014 to 2017; and the Chairman of Xceleron Inc. (bioanalytical services) from 2012 to 2017. He is also a member of the Strategic Advisory Board of Healthcare Royalty Partners, a position he has held since 2009. - Frank M. Armstrong自2013年9月起担任本公司董事。2010年12月至2011年12月领导默克雪兰诺公司的医学科学和创新研发。1998至2001年领导拜耳公司的全球产品开发。在1996至1998年领导在捷利康的全球医疗组织。2008至2010年还担任过Fulcrum制药有限公司的专业服务/ CRO的首席执行官；自2006年至2007年担任CURAGEN公司（肿瘤治疗）的总裁及行政总裁； 2003至2004年担任Provensis制药（BTG PLC（医疗）的附属公司）的行政总裁；2002至2003年担任PHOQUS制药有限公司的行政总裁。毕业于苏格兰爱丁堡大学，获生物化学医学士荣誉学位。在1994年当选为医药医师学院院士（FFPM），于1993年当选为爱丁堡（FRCPE）皇家内科医学院院士。自2013年6月起至今担任Summit PLC（药物发现和开发）的非执行主席； 自2012年4月起担任Xceleron公司（生物分析服务）的董事长，自2009年11月担任Actino制药的非执行董事； 自2013年9月起担任Entelos公司（生物模拟）的董事长；自2013年9月起担任CardioRentis有限公司（生物制药）的董事长。自2009年以来担任医疗保健版税合作伙伴的战略顾问委员会委员，自2009年以来担任英国的“爱非洲”慈善基金的主席。
- Frank M. Armstrong has been a director of the Company since September 2013. Dr. Armstrong led Medical Science and Innovation in R&D at Merck Serono from 2010 to 2011 and previously led Worldwide Product Development at Bayer AG from 1998 to 2001 and the Worldwide Medical Organization at Zeneca from 1996 to 1998. He also served as Chief Executive Officer of Fulcrum Pharma plc professional services/CRO from 2008 to 2010; President and Chief Executive Officer of CuraGen Corp. (oncology therapeutics) from 2006 to 2007; Chief Executive Officer of Bioaccelerate from 2005 to 2006; Chief Executive Officer of Provensis Pharmaceuticals, a subsidiary of BTG PLC (healthcare), from 2003 to 2004; and Chief Executive Officer of Phoqus Pharmaceuticals plc (drug delivery) from 2002 to 2003. Since 2012 Dr. Armstrong has served as a Director of Dr. Frank M Armstrong Consulting Ltd. Dr. Armstrong holds an honours degree in Biochemistry and MBChB in Medicine from the University of Edinburgh in Scotland. He was elected as a Fellow of the Faculty of Pharmaceutical Physicians (FFPM) in 1994 and Fellow of Royal College of Physicians, Edinburgh (FRCPE) in 1993. Dr. Armstrong is currently the non-executive Chairman of Summit plc (drug discovery and development), a position he has held since June 2013; the non-executive Chairman of Caldan Therapeutics (metabolic disease), a position he has held since March 2016; the non-executive Chairman of Faron Pharmaceuticals (drug discovery and development), a position he has held since September 2015; and a non-executive Director of Mereo Biopharma (drug discovery and development), a position he has held since July 2015. He served as the executive Chairman of Asceneuron SA (biotechnology) from 2012 to 2013; the non-executive Chairman of RedXPharma (drug discovery and development) from 2014 to 2017; and the Chairman of Xceleron Inc. (bioanalytical services) from 2012 to 2017. He is also a member of the Strategic Advisory Board of Healthcare Royalty Partners, a position he has held since 2009.
- Nikin Patel
-
Nikin Patel，自2013年9月Molecular Profiles被本公司收购起，一直担任本公司董事。 他是Molecular Profiles Ltd的成立行政总裁，自1998年10月起担任该职务。持有英国诺丁汉大学的一级荣誉学位和药学博士学位，是英国皇家药学会MRPharmS的成员。除了担任哥伦比亚实验室的董事，自2001年以来还一直担任Regentec有限公司（再生医学）的董事。
Nikin Patel was co-founded Juniper Pharma Services Ltd. f/k/a Molecular Profiles, Ltd. and served as its Chief Executive Officer from 1998 until April 2015 at which time he was named Chief Operating Officer of Juniper Pharmaceuticals, Inc. and President of Juniper Pharma Services Ltd. Dr. Patel joined our Board in September 2013 when Juniper Pharma Services was acquired by us. Dr. Patel is also a co-founder of Locate Therapeutics Ltd. (a specialist regenerative medicine and device company) and was a director from 2001 through 2014. Dr. Patel holds a first class honours degree and Ph.D. in Pharmacy from the University of Nottingham, and is a Member of the Royal Pharmaceutical Society (MRPharmS). - Nikin Patel，自2013年9月Molecular Profiles被本公司收购起，一直担任本公司董事。 他是Molecular Profiles Ltd的成立行政总裁，自1998年10月起担任该职务。持有英国诺丁汉大学的一级荣誉学位和药学博士学位，是英国皇家药学会MRPharmS的成员。除了担任哥伦比亚实验室的董事，自2001年以来还一直担任Regentec有限公司（再生医学）的董事。
- Nikin Patel was co-founded Juniper Pharma Services Ltd. f/k/a Molecular Profiles, Ltd. and served as its Chief Executive Officer from 1998 until April 2015 at which time he was named Chief Operating Officer of Juniper Pharmaceuticals, Inc. and President of Juniper Pharma Services Ltd. Dr. Patel joined our Board in September 2013 when Juniper Pharma Services was acquired by us. Dr. Patel is also a co-founder of Locate Therapeutics Ltd. (a specialist regenerative medicine and device company) and was a director from 2001 through 2014. Dr. Patel holds a first class honours degree and Ph.D. in Pharmacy from the University of Nottingham, and is a Member of the Royal Pharmaceutical Society (MRPharmS).
高管简历
中英对照 | 中文 | 英文- Bridget Martell
Bridget Martell，她曾监管许多制药公司（包括Purdue Pharma公司，以及Pfizer Worldwide公司的生物制药企业的几个业务部门）的产品开发活动。任职Purdue Pharma公司期间（从2011年10月到2013年4月），她曾领导并建立一个新的医疗事务组织，并支持在线和开发药物组合。任职Purdue Pharma公司之前，她曾担任Pfizer公司的生物仿制药品医疗负责人，在那里她负责临床开发和医疗事务活动（从2010年8月到2011年8月）。她也曾担任Pfizer公司的生物制药企业的其它业务单位的高级临床开发职务。最近，她曾担任BAM Consultants公司（为广泛的专业制药公司提供临床开发和医疗事务咨询服务）的创始人兼董事总经理（从2013年4月到2015年1月）。
Bridget Martell has served as a director since March 2021. Dr. Martell has served as Acting Chief Medical Officer of Nobias Therapeutics from August 2020 to present and for Verseau Therapeutics since December 2020. In October 2017 Dr. Martell began working with Kura Oncology, a clinical-stage biopharmaceutical company, where she served as VP, Clinical Development from October 2017 to January 2020 as Acting Chief Medical Officer from January 2020 to August 2020 and as Senior Scientific Advisor since August 2020. Concurrently, Dr. Martell served as Chief Medical Officer of RRD International, a boutique Contract Research Organization from April 2018 to January 2020. From January 2015 to September 2017 Dr. Martell served as Senior Vice President, New Product Development at Juniper Pharmaceuticals, a publicly-held specialty pharmaceuticals company. From October 2011 to April 2013 she was Executive Director, Head Medical Affairs at Purdue Pharma L.P., a privately-held pharmaceutical company. Previous to that, Dr. Martell held leadership roles of increasing responsibility at Pfizer, Inc., a publicly-held biopharmaceutical company from 2005 to 2011. Dr. Martell earned her B.S. in microbiology from Cornell University, her M.A. in molecular immunology from Boston University and her M.D. from the Chicago Medical School. She completed her internship and residency in internal medicine and was an internal medicine chief resident and RWJ Faculty Clinical Scholar at Yale University. Dr. Martell is board certified in both internal and addiction medicine.- Bridget Martell，她曾监管许多制药公司（包括Purdue Pharma公司，以及Pfizer Worldwide公司的生物制药企业的几个业务部门）的产品开发活动。任职Purdue Pharma公司期间（从2011年10月到2013年4月），她曾领导并建立一个新的医疗事务组织，并支持在线和开发药物组合。任职Purdue Pharma公司之前，她曾担任Pfizer公司的生物仿制药品医疗负责人，在那里她负责临床开发和医疗事务活动（从2010年8月到2011年8月）。她也曾担任Pfizer公司的生物制药企业的其它业务单位的高级临床开发职务。最近，她曾担任BAM Consultants公司（为广泛的专业制药公司提供临床开发和医疗事务咨询服务）的创始人兼董事总经理（从2013年4月到2015年1月）。
- Bridget Martell has served as a director since March 2021. Dr. Martell has served as Acting Chief Medical Officer of Nobias Therapeutics from August 2020 to present and for Verseau Therapeutics since December 2020. In October 2017 Dr. Martell began working with Kura Oncology, a clinical-stage biopharmaceutical company, where she served as VP, Clinical Development from October 2017 to January 2020 as Acting Chief Medical Officer from January 2020 to August 2020 and as Senior Scientific Advisor since August 2020. Concurrently, Dr. Martell served as Chief Medical Officer of RRD International, a boutique Contract Research Organization from April 2018 to January 2020. From January 2015 to September 2017 Dr. Martell served as Senior Vice President, New Product Development at Juniper Pharmaceuticals, a publicly-held specialty pharmaceuticals company. From October 2011 to April 2013 she was Executive Director, Head Medical Affairs at Purdue Pharma L.P., a privately-held pharmaceutical company. Previous to that, Dr. Martell held leadership roles of increasing responsibility at Pfizer, Inc., a publicly-held biopharmaceutical company from 2005 to 2011. Dr. Martell earned her B.S. in microbiology from Cornell University, her M.A. in molecular immunology from Boston University and her M.D. from the Chicago Medical School. She completed her internship and residency in internal medicine and was an internal medicine chief resident and RWJ Faculty Clinical Scholar at Yale University. Dr. Martell is board certified in both internal and addiction medicine.
- Jeffrey Young
Jeffrey Young自2017年1月起担任我们的首席财务官。在Ovascience之前，Young先生于2013年8月至2014年8月担任TransMedics，Inc.的首席财务官兼财务主管，领导财务、会计、税务和财务职能。在加入TransMedics之前，Young从2008年9月到2013年8月担任Lantheus Medical Imaging，Inc.（一家国际公司）首席财务官和财务主管。任职Lantheus公司期间，他曾负责多种职能，包括财务、会计、客户服务、税务和财政。在Lantheus之前，Young先生从2005年到2008年担任Critical Therapeutics Inc.的首席会计官、财务Vice President和财务主管，并在该公司被Cornerstone Biopharma收购期间管理公司的过渡。在职业生涯早期，杨致远曾在珀金埃尔默公司担任财务职位，并在普华永道会计师事务所（PricewaterhouseCoopers LLP）担任注册会计师。Young先生拥有乔治敦大学（Georgetown University）工商管理学士学位。
Jeffrey Young has served as our Chief Financial Officer since January 2017. Before OvaScience, Mr. Young served as Chief Financial Officer and Treasurer of Transmedics, Inc. from August 2013 to August 2014, leading the finance, accounting, tax and treasury functions. Prior to Transmedics, Mr. Young was Chief Financial Officer and Treasurer at Lantheus Medical Imaging, Inc., an international corporation, from September 2008 to August 2013. While at Lantheus, he was responsible for multiple functions, including finance, accounting, customer service, tax and treasury. Before Lantheus, Mr. Young served as Chief Accounting Officer, Vice President of Finance and Treasurer at Critical Therapeutics Inc. from 2005 to 2008, and managed the company's transition during its acquisition by Cornerstone BioPharma. Earlier in his career, Mr. Young held finance roles at PerkinElmer, Inc. and began his career as a Certified Public Accountant at PricewaterhouseCoopers LLP. Mr. Young holds a B.S. in Business Administration from Georgetown University.- Jeffrey Young自2017年1月起担任我们的首席财务官。在Ovascience之前，Young先生于2013年8月至2014年8月担任TransMedics，Inc.的首席财务官兼财务主管，领导财务、会计、税务和财务职能。在加入TransMedics之前，Young从2008年9月到2013年8月担任Lantheus Medical Imaging，Inc.（一家国际公司）首席财务官和财务主管。任职Lantheus公司期间，他曾负责多种职能，包括财务、会计、客户服务、税务和财政。在Lantheus之前，Young先生从2005年到2008年担任Critical Therapeutics Inc.的首席会计官、财务Vice President和财务主管，并在该公司被Cornerstone Biopharma收购期间管理公司的过渡。在职业生涯早期，杨致远曾在珀金埃尔默公司担任财务职位，并在普华永道会计师事务所（PricewaterhouseCoopers LLP）担任注册会计师。Young先生拥有乔治敦大学（Georgetown University）工商管理学士学位。
- Jeffrey Young has served as our Chief Financial Officer since January 2017. Before OvaScience, Mr. Young served as Chief Financial Officer and Treasurer of Transmedics, Inc. from August 2013 to August 2014, leading the finance, accounting, tax and treasury functions. Prior to Transmedics, Mr. Young was Chief Financial Officer and Treasurer at Lantheus Medical Imaging, Inc., an international corporation, from September 2008 to August 2013. While at Lantheus, he was responsible for multiple functions, including finance, accounting, customer service, tax and treasury. Before Lantheus, Mr. Young served as Chief Accounting Officer, Vice President of Finance and Treasurer at Critical Therapeutics Inc. from 2005 to 2008, and managed the company's transition during its acquisition by Cornerstone BioPharma. Earlier in his career, Mr. Young held finance roles at PerkinElmer, Inc. and began his career as a Certified Public Accountant at PricewaterhouseCoopers LLP. Mr. Young holds a B.S. in Business Administration from Georgetown University.
- Alicia Secor
Alicia Secor.， 自2014年1月起担任首席商务官。她在制药、生物技术和医疗设备方面有着20多年的经验。她在通过生命周期发展各个阶段引领商业发展并进行产品全球扩张领域，包括发射前和后期的商业阶段涵盖多个治疗领域，包括代谢性疾病，有着良好的记录。从2013年8月到2013年10月担任Synageva BioPharma Corp高级副总裁和首席运营官。之前从1998年11月到2013年7月，她在 Genzyme Corporation（一家Sanofi 公司）工作15年，担任多个领导职位，最近的职位是担任Metabolic Diseases（一家全球业务，包括5大产品销售，其中又包括治疗罕见疾病的两种产品）副总裁和总经理。在此之前，她还担任Biosurgical Specialties（一家手术设备业务，重点关注防粘粘和生物材料的新应用）副总裁和总经理。在Genzyme任职期间，她在通过临床开发和负责建立以及执行商业开发和推出，一般管理和全球扩张以推广产品方面发挥了很大作用。她成功地带领了多元战略业务开发拍卖会，负责全球的P&L，并建立高绩效团队，从而带来了多个业务的持续增长和盈利能力。加入 Genzyme之前，她在 Alkermes plc 的业务开发部门、Centocor, Inc.（一家Johnson & Johnson公司）的临床和商务运营部门担任多个职位；她在 Pfizer Inc.担任以医院为基础的销售代表开启自己的职业生涯。她持有东北大学（Northeastern University）工商管理硕士学位以及the University of New Hampshire医疗保健管理理学学士学位。
Alicia Secor joined our board of directors in December 2017.Ms. Secor served as President and Chief Executive Officer of Juniper Pharmaceuticals, Inc., a Nasdaq listed pharmaceutical company from August 2016 until August 2018 the date the company was acquired by Catalent, Inc. Previously, she served as the chief commercial officer of Zafgen Inc., a biopharmaceutical company, from January 2014 to July 2016. From August 2013 to October 2013 she served as senior vice president and chief operating officer of Synageva BioPharma Corp., a biotechnology company. Previously, from November 1998 to July 2013 Ms. Secor spent 15 years at Genzyme, a biotechnology company, where she held various leadership positions, most recently as vice president and general manager of Metabolic Diseases, a global business with five marketed products, including two products for orphan diseases. Prior to this role, she was vice president and general manager of Biosurgical Specialties, a surgical device business focused on adhesion prevention and other novel applications for biomaterials. Prior to Genzyme, Ms. Secor held positions at Alkermes, Inc. in business development, at Centocor, Inc. a Johnson & Johnson company in clinical and commercial operations, and began her career at Pfizer Inc. as a hospital-based sales representative. Ms. Secor also serves as a member of the board of directors for the Foundation for Prader-Willi Research. She received her M.B.A. from Northeastern University and her B.S. in Healthcare Administration from the University of New Hampshire.- Alicia Secor.， 自2014年1月起担任首席商务官。她在制药、生物技术和医疗设备方面有着20多年的经验。她在通过生命周期发展各个阶段引领商业发展并进行产品全球扩张领域，包括发射前和后期的商业阶段涵盖多个治疗领域，包括代谢性疾病，有着良好的记录。从2013年8月到2013年10月担任Synageva BioPharma Corp高级副总裁和首席运营官。之前从1998年11月到2013年7月，她在 Genzyme Corporation（一家Sanofi 公司）工作15年，担任多个领导职位，最近的职位是担任Metabolic Diseases（一家全球业务，包括5大产品销售，其中又包括治疗罕见疾病的两种产品）副总裁和总经理。在此之前，她还担任Biosurgical Specialties（一家手术设备业务，重点关注防粘粘和生物材料的新应用）副总裁和总经理。在Genzyme任职期间，她在通过临床开发和负责建立以及执行商业开发和推出，一般管理和全球扩张以推广产品方面发挥了很大作用。她成功地带领了多元战略业务开发拍卖会，负责全球的P&L，并建立高绩效团队，从而带来了多个业务的持续增长和盈利能力。加入 Genzyme之前，她在 Alkermes plc 的业务开发部门、Centocor, Inc.（一家Johnson & Johnson公司）的临床和商务运营部门担任多个职位；她在 Pfizer Inc.担任以医院为基础的销售代表开启自己的职业生涯。她持有东北大学（Northeastern University）工商管理硕士学位以及the University of New Hampshire医疗保健管理理学学士学位。
- Alicia Secor joined our board of directors in December 2017.Ms. Secor served as President and Chief Executive Officer of Juniper Pharmaceuticals, Inc., a Nasdaq listed pharmaceutical company from August 2016 until August 2018 the date the company was acquired by Catalent, Inc. Previously, she served as the chief commercial officer of Zafgen Inc., a biopharmaceutical company, from January 2014 to July 2016. From August 2013 to October 2013 she served as senior vice president and chief operating officer of Synageva BioPharma Corp., a biotechnology company. Previously, from November 1998 to July 2013 Ms. Secor spent 15 years at Genzyme, a biotechnology company, where she held various leadership positions, most recently as vice president and general manager of Metabolic Diseases, a global business with five marketed products, including two products for orphan diseases. Prior to this role, she was vice president and general manager of Biosurgical Specialties, a surgical device business focused on adhesion prevention and other novel applications for biomaterials. Prior to Genzyme, Ms. Secor held positions at Alkermes, Inc. in business development, at Centocor, Inc. a Johnson & Johnson company in clinical and commercial operations, and began her career at Pfizer Inc. as a hospital-based sales representative. Ms. Secor also serves as a member of the board of directors for the Foundation for Prader-Willi Research. She received her M.B.A. from Northeastern University and her B.S. in Healthcare Administration from the University of New Hampshire.
- Nikin Patel
Nikin Patel，自2013年9月Molecular Profiles被本公司收购起，一直担任本公司董事。 他是Molecular Profiles Ltd的成立行政总裁，自1998年10月起担任该职务。持有英国诺丁汉大学的一级荣誉学位和药学博士学位，是英国皇家药学会MRPharmS的成员。除了担任哥伦比亚实验室的董事，自2001年以来还一直担任Regentec有限公司（再生医学）的董事。
Nikin Patel was co-founded Juniper Pharma Services Ltd. f/k/a Molecular Profiles, Ltd. and served as its Chief Executive Officer from 1998 until April 2015 at which time he was named Chief Operating Officer of Juniper Pharmaceuticals, Inc. and President of Juniper Pharma Services Ltd. Dr. Patel joined our Board in September 2013 when Juniper Pharma Services was acquired by us. Dr. Patel is also a co-founder of Locate Therapeutics Ltd. (a specialist regenerative medicine and device company) and was a director from 2001 through 2014. Dr. Patel holds a first class honours degree and Ph.D. in Pharmacy from the University of Nottingham, and is a Member of the Royal Pharmaceutical Society (MRPharmS).- Nikin Patel，自2013年9月Molecular Profiles被本公司收购起，一直担任本公司董事。 他是Molecular Profiles Ltd的成立行政总裁，自1998年10月起担任该职务。持有英国诺丁汉大学的一级荣誉学位和药学博士学位，是英国皇家药学会MRPharmS的成员。除了担任哥伦比亚实验室的董事，自2001年以来还一直担任Regentec有限公司（再生医学）的董事。
- Nikin Patel was co-founded Juniper Pharma Services Ltd. f/k/a Molecular Profiles, Ltd. and served as its Chief Executive Officer from 1998 until April 2015 at which time he was named Chief Operating Officer of Juniper Pharmaceuticals, Inc. and President of Juniper Pharma Services Ltd. Dr. Patel joined our Board in September 2013 when Juniper Pharma Services was acquired by us. Dr. Patel is also a co-founder of Locate Therapeutics Ltd. (a specialist regenerative medicine and device company) and was a director from 2001 through 2014. Dr. Patel holds a first class honours degree and Ph.D. in Pharmacy from the University of Nottingham, and is a Member of the Royal Pharmaceutical Society (MRPharmS).